An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
histologically or cytologically proven diagnosis of non-small cell lung cancer
positive for the ALK fusion gene (test provided by a central laboratory)
must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug
tumors must be measurable
You may not be if
prior treatment with PF-02341066
current treatment in another clinical trial
Clareo Health | An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
